Print Page  |  Close Window

SEC Filings

6-K
TEVA PHARMACEUTICAL INDUSTRIES LTD filed this Form 6-K on 08/03/2017
Entire Document
 


Table of Contents

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

CONSOLIDATED BALANCE SHEETS

(U.S. dollars in millions)

(Unaudited)

 

     June 30,     December 31,  
     2017     2016  

ASSETS

    

Current assets:

    

Cash and cash equivalents

   $ 599     $ 988  

Trade receivables

     7,320       7,523  

Inventories

     5,132       4,954  

Prepaid expenses

     871       1,362  

Other current assets

     652       1,293  

Assets held for sale

     21       841  
  

 

 

   

 

 

 

Total current assets

     14,595       16,961  

Deferred income taxes

     773       725  

Other non-current assets

     1,245       1,235  

Property, plant and equipment, net

     8,043       8,073  

Identifiable intangible assets, net

     21,664       21,487  

Goodwill

     40,035       44,409  
  

 

 

   

 

 

 

Total assets

   $ 86,355     $ 92,890  
  

 

 

   

 

 

 

LIABILITIES AND EQUITY

    

Current liabilities:

    

Short-term debt

   $ 1,246     $ 3,276  

Sales reserves and allowances

     7,565       7,839  

Trade payables

     2,278       2,157  

Employee-related obligations

     712       859  

Accrued expenses

     2,758       3,405  

Other current liabilities

     898       867  

Liabilities held for sale

     —         116  
  

 

 

   

 

 

 

Total current liabilities

     15,457       18,519  

Long-term liabilities:

    

Deferred income taxes

     5,446       5,215  

Other taxes and long-term liabilities

     2,038       1,639  

Senior notes and loans

     33,806       32,524  
  

 

 

   

 

 

 

Total long-term liabilities

     41,290       39,378  
  

 

 

   

 

 

 

Commitments and contingencies, see note 16

    

Total liabilities

     56,747       57,897  
  

 

 

   

 

 

 

Equity:

    

Teva shareholders’ equity:

    

Preferred shares of NIS 0.10 par value per mandatory convertible preferred share; June 30, 2017 and December 31, 2016: authorized 5.0 million shares; issued 3.7 million shares

     3,620       3,620  

Ordinary shares of NIS 0.10 par value per share; June 30, 2017 and December 31, 2016: authorized 2,495 million shares; issued 1,123 million shares

     54       54  

Additional paid-in capital

     23,444       23,409  

Retained earnings

     7,430       13,607  

Accumulated other comprehensive loss

     (2,400     (3,159

Treasury shares as of June 30, 2017 and December 31, 2016 —107 million ordinary shares and 108 million ordinary shares, respectively

     (4,154     (4,194
  

 

 

   

 

 

 
     27,994       33,337  
  

 

 

   

 

 

 

Non-controlling interests

     1,614       1,656  
  

 

 

   

 

 

 

Total equity

     29,608       34,993  
  

 

 

   

 

 

 

Total liabilities and equity

   $ 86,355     $ 92,890  
  

 

 

   

 

 

 

 

/s/ DR. Y. PETERBURG

    

/s/ M. MCCLELLAN

Dr. Y. Peterburg

Interim President and Chief Executive Officer

    

M. McClellan

Senior Vice President and

Interim Chief Financial Officer

The accompanying notes are an integral part of the financial statements.

 

3